Age-related cataract
Conditions
Interventions
Experimental: Remote follow-up:Remote follow-up 1 week after cataract surgery
No Intervention: Usual care:Routine follow-up one week after cataract surgery.
Sponsors
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients aged 50–80 years (inclusive), regardless of gender, undergoing phacoemulsification with intraocular lens (IOL) implantation under local anesthesia for age-related cataract. 2.Ownership of or access to a smartphone, with the ability (independently or with family assistance) to install and use the WHOeyes application for vision testing. 3.Ability to understand and comply with the study procedures, with voluntary participation and signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Chronic or recurrent conditions in the surgical eye, such as keratitis, corneal dystrophy, iritis, scleritis, uveitis, or iridocyclitis,excluding conditions that do not significantly affect visual acuity (e.g., refractive errors, dry eye, chronic conjunctivitis, and mild pterygium, etc.). 2.Active infection or inflammation in either eye. 3.History of acute uveitis in either eye within the past 6 months. 4.Intraocular pressure >21 mmHg in the surgical eye or a history of glaucoma. 5.Unstable or active ocular conditions in the surgical eye that may affect study evaluations or patient safety, such as moderate to severe diabetic retinopathy, wet age-related macular degeneration, or retinal detachment. 6.Congenital abnormalities in the surgical eye (e.g., congenital cataract, aniridia). 7.Corrected visual acuity 10 mmol/L). 14.Poorly controlled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg). 15.Active infectious diseases requiring systemic treatment. 16.Cachexia or bone marrow suppression. 17.History of acquired immunodeficiency syndrome (AIDS) or HIV-positive status. 18.Other severe cardiovascular, pulmonary, hepatic, renal, endocrine, immune, dermatological, musculoskeletal, neurological, or psychiatric disorders, or disabilities (e.g., hearing impairment or mobility issues) that, in the investigator's opinion, make the patient unsuitable for participation. 19.Participation in another clinical trial within 1 month prior to screening (excluding trials involving only screening without use of investigational drugs or devices). 20.Any other planned follow-up visits unrelated to the study during the trial period. 21.Other conditions deemed unsuitable for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The best corrected distant visual acuity in the operative eye 1 month after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| incremental cost-effectiveness ratio (ICER);Carbon emission;Uncorrected distant visual acuity (UDVA) of the operative eye;Incidence and severity of postoperative complications;Incidence and severity of self-reported ocular discomfort;Number of unplanned visits;Patient reported outcome measures (PROMs): Catquest-9SF;Patient reported outcome measures (PROMs): NEI-VFQ-25;Patient reported outcome measures (PROMs): EQ-5D-5L;Users' satisfaction with the WHOeyes app.; | — |
Countries
China
Contacts
Public ContactLuo Lixia
The Zhongshan Ophthalmic Center,Sun Yat-sen University
Outcome results
None listed